Showing 3311-3320 of 4165 results for "".
- Horizon Therapeutics Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head Onhttps://modernod.com/news/horizon-therapeutics-launches-letter-writing-campaign-to-empower-those-living-with-thyroid-eye-disease-ted-to-confront-the-condition-head-on/2480860/For Mental Health Awareness Month and Healthy Vision Month in May, Horizon Therapeutics is partnering with mental health expert and New York Times best-selling author, Lori Gottlieb, to highlight the emotional burden of living with TED—a serious, progressive, and poten
- Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technologyhttps://modernod.com/news/clearside-biomedical-poster-presentation-at-arvo-2022-annual-meeting-demonstrates-versatility-of-suprachoroidal-delivery-technology/2480845/Clearside Biomedical, Inc. announced that several poster presentations were delivered on Clearside’s proprietary suprachoroidal delivery platform, XIPERE®, and gene therapy delivery utilizing Clearside’s SCS Microinjector® at the Association for Research in Vision and Ophthalm
- SAV-IOL Launches Instant Focus EDOF IOL Technologyhttps://modernod.com/news/sav-iol-launches-instant-focus-edof-iol-technology/2480841/Instant Focus is a unique optical technology designed by Swiss IOL maker SAV-IOL (Swiss Advanced Vision). The technology is designed to replace the accommodative function of the eye’s natural lens after cataract surgery, and is manufactured and marketed directly from their he
- Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03https://modernod.com/news/bausch-lomb-presents-data-from-second-pivotal-phase-3-trial-of-investigational-treatment-nov03-at-arvo/2480837/Bausch + Lomb and Novaliq announced that data from the second pivotal phase 3 trial (MOJAVE) of investigational treatment NOV03 (perfluorohexyloctane) were presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. NOV03 is being investigated as a first-in-c
- Oxurion Announces Preclinical Data on THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-announces-preclinical-data-on-thr-687-for-the-treatment-of-dme-at-arvo/2480836/Oxurion presented preclinical data from a study evaluating THR-687 for treatment of diabetic macular edema (DME) at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Preclinical data shows THR-687's 
- Ashvattha Therapeutics Presents Phase 1 Safety Data in Healthy Subjects for Subcutaneous Anti-VEGF Wet AMD and DME Candidatehttps://modernod.com/news/ashvattha-therapeutics-presents-phase-1-safety-data-in-healthy-subjects-for-subcutaneous-anti-vegf-wet-amd-and-dme-candidate/2480829/Ashvattha Therapeutics announced the presentation of safety data from a phase 1 study of its lead candidate D-4517.2, a VEGFR/PDGFR tyrosine kinase inhibitor conjugated to a hydroxyl dendrimer, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in
- Atsena Therapeutics Announces Presentations at ARVO and ASGCThttps://modernod.com/news/atsena-therapeutics-announces-presentations-at-arvo-and-asgct/2480825/Atsena Therapeutics announced that research on two of its next-generation adeno-associated virus (AAV) technologies will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, and the American Society of Gene & Cell Therapy (ASGC
- Nicox Presents Phase 2 Results on NCX 4251 and New Nonclinical Evidence of Improved Hemodynamic and Retinal Cell Physiology on NCX 470https://modernod.com/news/nicox-presents-phase-2-results-on-ncx-4251-and-new-nonclinical-evidence-of-improved-hemodynamic-and-retinal-cell-physiology-on-ncx-470/2480822/Nicox SA announced poster presentations highlighting the effect of NCX 4251 in patients with dry eye disease as well as new nonclinical evidence of neuroprotective activity on NCX 470 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 annual meeting, one of the key scien
- Allergan to Present New Data from its Portfolio of Eye Care Treatments at ARVOhttps://modernod.com/news/allergan-to-present-new-data-from-its-portfolio-of-eye-care-treatments-at-arvo/2480817/Allergan announced that it will present new data on Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the first and only FDA-approved eye drop for the treatment of presbyopia (age-related blurry near vision) in adults, and Durysta (bimatoprost
- Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During ARVOhttps://modernod.com/news/bausch-lomb-will-present-new-scientific-data-and-analyses-on-products-and-pipeline-programs-during-arvo/2480814/Bausch + Lomb announced the presentation of 13 scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in Denver, Colorado, from May 1-4, 2022, and virtually from May 11-12, 2022. The presentations incl